Copaxone
Mylan looks to hit Teva where it hurts, eyeing slow-release MS treatment
April 11, 2018Research and Development, Sales and Marketing Copaxone, Mapi Pharma, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, …
Mylan receives shock approval of Teva blockbuster
October 5, 2017Sales and Marketing Copaxone, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Mylan had been knocked back by the FDA in its quest to have its generic version of Copaxone approved earlier …
US Congressmen accuse Teva of price hikes over 1,000%
August 21, 2017Sales and Marketing Copaxone, Teva, life sciences, medicine, multiple sclerosis, pharma, pharmaceutical, price hiking
A pair of US Congressmen have fired allegations at Israeli drugmaker Teva accusing the firm of hiking the price of …
Pfizer plant receives FDA warning letter for contamination of medicine
March 1, 2017Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics
The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …
Teva sets out to delay generic competitor to Copaxone
October 31, 2016Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics
Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …
Teva loses patent protection on lucrative MS treatment
August 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
US Supreme Court backs Teva in Copaxone patent case
January 28, 2015Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva
Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …
Takeda trials Teva Parkinson’s drug in Japan
January 9, 2015Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline
Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …
Teva to ditch R&D in cancer and women’s health
October 6, 2014Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics
Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …
Teva considers up to 27 plant closures
May 13, 2014Manufacturing and Production, Sales and Marketing Copaxone, Nerventra, Teva, cuts, generics
Teva is to close 11 of its production sites, with another 16 facilities ‘under evaluation’, as part of a major …
Teva under investigation for marketing practices
February 12, 2014Sales and Marketing Azilect, Copaxone, Teva, fines, generics
Teva Pharmaceuticals is under investigation by US authorities for sales and marketing activity around two of its drugs – including …
High-dose Copaxone the right medicine for Teva
January 29, 2014Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva
The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …
Teva boss quits over Board struggles
October 31, 2013Medical Communications, Sales and Marketing Copaxone, Levin, Teva, generics
Teva’s president and chief executive Dr Jeremy Levin has unexpectedly quit as the firm struggles with staff cuts and management …
Teva to axe 5,000 jobs in savings drive
October 11, 2013Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, Teva, cuts
The world’s largest generic drugmaker Teva will cut around 5,000 jobs from its global workforce as it looks to speed-up …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
